Asthmanefrin Racephinephrine Inhalation Solution Recalled Due to Improper Storage
Asthmanefrin Racephinephrine Inhalation Solution is being recalled because batches were stored outside the conditions specified on the drug label. The recall affects products distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses, injuries, or deaths. The recall is due to a CGMP compliance deviation (improper storage) without documented safety incidents, qualifying it as a quality control matter rather than an active safety threat.
Plain-English summary
Asthmanefrin Racephinephrine Inhalation Solution, a bronchodilator for temporary relief of mild symptoms of intermittent asthma, is being recalled. The recall affects products distributed nationwide in the United States.
The product is being recalled due to a CGMP (good manufacturing practices) deviation: products were stored outside the conditions specified on the drug label. This storage deviation was identified by McKesson Medical-Surgical Inc., the recalling firm.
Consumers who have obtained this product should consult with their healthcare provider or pharmacist regarding whether continued use is appropriate.
The recalled product
- Product
- Asthmanefrin Racephinephrine Inhalation Solution Bronchodilator, For temporary relief of mild symptoms of intermittent asthma, Preservative Free, Sterile, For Oral Inhalation Only, 30 vials per box, Nephron Pharmaceuticals Corporation, NDC 0487-2784-01.
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug
- Hazard
- improper-storage
- cgmp-deviation
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27